Table 4.
Clinical characteristics and concentrations of Apolipoproteins in the AH of healthy controls and diabetic patients with non-apparent DR.
| Healthy controls1 (n = 17) | No apparent DR (n = 23) | p-value | |
|---|---|---|---|
| Age (years; mean ± SD) | 64.6 ± 10.8 | 71.6 ± 9.6 | 0.34 |
| Gender: | |||
| Females: n (%) | 16 (94) | 11 (48) | 0.002∗ |
| Duration of diabetes (years; mean ± SD) | N/A | 15.0 ± 12.9 | N/A |
| BMI (mean ± SD) | 24.6 ± 3 .7 | 28.8 ± 5.6 | 0.072 |
| Dyslipidemia (n; %) | 0 | 15 (65) | 0.0005∗ |
| Hypertension (n; %) | 0 | 17 (74) | 0.0005∗ |
| Apolipoproteins(mean ± SD;(median; IQR 25 – 75) ng/ml) | |||
| Apo AI | 175 ± 152 (121; 59-265) |
421 ± 446 (235; 93-801) |
0.08 |
| Apo AII | 75 ± 61 (59;24-120) |
178 ± 191 (104; 40-293) |
0.12 |
| Apo CI | 34 ± 21 (31; 14-50) |
60 ± 49 (42; 22-108) |
0.16 |
| Apo CIII | 1.5 ± 1.3 (1.2; 0.6-2.1) |
4.0 ± 4.5 (2.2; 1.0-5.8) |
0.053 |
| Apo D | 24 ± 10 (22; 17-29) |
34 ± 17 (29; 17-50) |
0.14 |
| Apo E | 72 ± 28 (75; 45-93) |
95 ± 73 (79; 41-127) |
0.54 |
| Apo H | 430 ± 243 (337; 288-586) |
664 ± 539 (484; 275-943) |
0.26 |
| Apo J | 401 ± 171 (384; 268-455) |
640 ± 452 (564; 302-805) |
0.11 |
1 Definition of healthy controls: no underlying disease, no medication.